Novel cd3 epsilon immunogens and antibodies

Abstract

The present invention relates to novel CD3 epsilon peptides, antibodies against the novel CD3 epsilon peptides. The invention also relates to methods of identifying an immunodeficiency (such as severe combined immunodeficiency (SCID) or a T cell immunodeficiency) in a patient, which may involve antibodies against CD3 epsilon peptides.

1 . An isolated CD3 epsilon peptide comprising residues 8-12 of SEQ ID NO: 1. 
     
     
         2 . An isolated CD3 epsilon peptide comprising residues 6-10 of SEQ ID NO: 2. 
     
     
         3 . (canceled) 
     
     
         4 . An isolated CD3 epsilon peptide consisting of 10 residues wherein residues 6-10 of the peptide are residues 6-10 of SEQ ID NO: 2. 
     
     
         5 . (canceled) 
     
     
         6 . An isolated CD3 epsilon peptide consisting of SEQ ID NO: 2. 
     
     
         7 . An isolated antibody against the peptide of  claim 1 . 
     
     
         8 . An isolated antibody against the peptide of  claim 2 . 
     
     
         9 . An isolated antibody against the peptide of  claim 3 . 
     
     
         10 . An isolated antibody against the peptide of  claim 4 . 
     
     
         11 . An isolated antibody against the peptide of  claim 5 . 
     
     
         12 . An isolated antibody against the peptide of  claim 6 . 
     
     
         13 . A method of identifying an immunodeficiency in a patient, comprising isolating a blood sample from the patient and performing an immunoassay on the blood sample with the antibody of any one of  claims 7 - 12 . 
     
     
         14 . The method of  claim 13 , wherein the immunodeficiency is severe combined immunodeficiency (SCID). 
     
     
         16 . The method of  claim 13 , wherein the immunodeficiency is a T cell immunodeficiency.